Danuglipron

Danuglipron is a small-molecule GLP-1 agonist developed by Pfizer[1] that, in an oral formulation, is under investigation as a therapy for diabetes mellitus. Initial results from a randomized controlled trial indicate that it reduced weight[2] and improved diabetic control. The most commonly reported adverse events were nausea, diarrhea, and vomiting.[3][4]

Danuglipron
Clinical data
Other namesPF-06882961
Legal status
Legal status
  • Investigational
Identifiers
  • 2-[[4-[6-[(4-Cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid
CAS Number
PubChem CID
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC31H30FN5O4
Molar mass555.610 g·mol−1
3D model (JSmol)
  • C1CO[C@@H]1CN2C3=C(C=CC(=C3)C(=O)O)N=C2CN4CCC(CC4)C5=NC(=CC=C5)OCC6=C(C=C(C=C6)C#N)F
  • InChI=1S/C31H30FN5O4/c32-25-14-20(16-33)4-5-23(25)19-41-30-3-1-2-26(35-30)21-8-11-36(12-9-21)18-29-34-27-7-6-22(31(38)39)15-28(27)37(29)17-24-10-13-40-24/h1-7,14-15,21,24H,8-13,17-19H2,(H,38,39)/t24-/m0/s1
  • Key:HYBAKUMPISVZQP-DEOSSOPVSA-N

See also

References
  1. Griffith DA, Edmonds DJ, Fortin JP, Kalgutkar AS, Kuzmiski JB, Loria PM, et al. (June 2022). "A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor". Journal of Medicinal Chemistry. 65 (12): 8208–8226. doi:10.1021/acs.jmedchem.1c01856. PMC 9234956. PMID 35647711.
  2. Medical Weight Loss
  3. Saxena AR, Frias JP, Brown LS, Gorman DN, Vasas S, Tsamandouras N, Birnbaum MJ (May 2023). "Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial". JAMA Network Open. 6 (5): e2314493. doi:10.1001/jamanetworkopen.2023.14493. PMC 10203889. PMID 37213102.
  4. Constantino, Annika Kim (2023-12-02). "Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops". CNBC. Retrieved 2023-12-03.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.